[1]史明旭a,宫 晶b,李小伟b.脑胶质瘤组织中YTHDF2，UBXN1的表达及其对预后的评估价值[J].现代检验医学杂志,2024,39(06):130-134+210.[doi:10.3969/j.issn.1671-7414.2024.06.022]
　SHI Mingxua,GONG Jingb,LI Xiaoweib.Expression of YTHDF2 and UBXN1 in Gliomas and Their Prognostic Value[J].Journal of Modern Laboratory Medicine,2024,39(06):130-134+210.[doi:10.3969/j.issn.1671-7414.2024.06.022]
点击复制

脑胶质瘤组织中YTHDF2，UBXN1的表达及其对预后的评估价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年06期
页码:
130-134+210
栏目:
论著
出版日期:
2024-11-15

文章信息/Info

Title:
Expression of YTHDF2 and UBXN1 in Gliomas and Their Prognostic Value
文章编号:
1671-7414（2024）06-130-06
作者:
史明旭a; 宫 晶b; 李小伟b
（青岛市胶州中心医院 a. 神经外科；b. 小儿科，青岛 266300）
Author(s):
SHI Mingxua;  GONG Jingb;  LI Xiaoweib
（a. Department of Neurosurgery；b. Department of Paediatrics, Qingdao Jiaozhou Central Hospital, Qingdao 266300, China）
关键词:
脑胶质瘤; YTH 结构域N6- 甲基腺嘌呤RNA 结合蛋白2; UBX 结构域蛋白1
分类号:
R739.41；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.06.022
文献标志码:
A
摘要:
目的 研究脑胶质瘤组织中YTH 结构域N6- 甲基腺嘌呤RNA 结合蛋白2 (YTH domain N6-methyladenine RNAbinding protein 2，YTHDF2)，UBX 结构域蛋白1(UBX domain protein 1，UBXN1) 的表达及预后评估价值。方法 选取2017 年2 月～ 2018 年2 月青岛市胶州中心医院诊治的92 例脑胶质瘤患者。免疫组织化学检测组织YTHDF2，UBXN1表达。相关性采用Spearman 秩相关分析。Kaplan-Meier 曲线分析YTHDF2，UBXN1 表达与脑胶质瘤患者预后的影响。COX 分析脑胶质瘤患者预后影响因素。结果 相比于癌旁组织，脑胶质瘤中YTHDF2（65.22% vs 15.22%）阳性率较高，UBXN1（26.09% vs 73.91%）的阳性率较低，差异具有统计学意义（χ2=47.831，42.087，均P ＜ 0.05）。Spearman 秩相关分析，脑胶质瘤中YTHDF2 与UBXN1 表达呈负相关（r= -0.712，P ＜ 0.05）。相比于肿瘤直径＜ 3cm，WHO 分级I ～ II 级，肿瘤直径≥ 3cm 和WHO 分级Ⅲ级脑胶质瘤组织中YTHDF2（75.47% vs 51.28%，65.22% vs 50.00%）阳性率较高，而UBXN1（15.09% vs 41.03%，11.11% vs 47.37%）阳性率较低，差异具有统计学意义（χ2=5.795，6.609；7.835，15.207，均P ＜ 0.05）。YTHDF2 阳性组五年总生存率低于阴性组[28.33%（17/60）vs 62.50%（20/32）]，UBXN1 阳性组五年总生存率高于阴性组[66.67%（16/24）vs 30.88%（21/68）]，差异具有统计学意义（Log-Rankχ2=12.870，7.665，均P ＜ 0.05）。YTHDF2 阳性（HR=2.427，95%CI：1.426 ～ 4.569）、UBXN1 阴性（HR=1.740，95%CI：1.121 ～ 2.568）、WHO 分级Ⅲ级（HR=2.671, 95%CI：1.160 ～ 6.012）及肿瘤直径≥ 3cm（HR=1.628, 95%CI：1.017 ～ 2.592）是胶质瘤患者不良预后的危险因素。结论 脑胶质瘤组织中YTHDF2 升高，UBXN1 降低，两者与WHO 分级及肿瘤直径有关。YTHDF2 和UBXN1 是评估脑胶质瘤患者预后的独立因素。
Abstract:
Objective This study aims to investigate the expression of YTH domain N6-methyladenine RNA binding protein 2 (YTHDF2) and UBX domain protein 1 (UBXN1) in glioma tissue and their prognostic value. Methods A total of 92 glioma cases that underwent surgical treatment in Qingdao Jiaozhou Central Hospital from February 2017 to February 2018 were included. Immunohistochemistry was used to detect YTHDF2 and UBXN1 expression. Spearman rank correlation analysis was conducted. Kaplan-Meier survival curves were plotted to analyze the association between YTHDF2, UBXN1 expression and prognosis in glioma patients. COX analysis was used to determine the prognostic factors affecting glioma patients. Results Compared with adjacent tissues, the positivity rate of YTHDF2 (65.22% vs 15.22%) was significantly higher in gliomas, while the positivity rate of UBXN1 (26.09% vs 73.91%) was lower, and differences were statistically significant （χ2=47.831, 42.087, all P<0.05). Spearman rank correlation analysis，showed a negative correlation between YTHDF2 and UBXN1 expression in gliomas (r= -0.712, P<0.05). Compared with tumors diameter < 3cm and WHO grades I to II, YTHDF2 （75.47% vs 51.28%，65.22% vs 50.00%）had a higher positivity rate in glioma tissues with tumor diameter ≥ 3cm and WHO grade Ⅲ, while UBXN1 （15.09% vs 41.03%，11.11% vs 47.37%） had a lower positivity rate, and differences were statistically significant (χ2=5.795，6.609；7.835，15.207，all P ＜ 0.05). The five-year overall survival rate of YTHDF2 positive group was lower than that of negative group [28.33% (17/60) vs 62.50% (20/32)], while the five-year overall survival rate of UBXN1 positive group was higher than that of negative group [66.67% (16/24) vs 30.88% (21/68)], and the differences were statistically significant (Log-Rank χ2=12.870, 7.665, all P<0.05). YTHDF2 positive（HR=2.427, 95%CI: 1.426 ～ 4.569）,UBXN1 negative（HR=1.740, 95%CI: 1.121 ～ 2.568）, WHO grade III（HR=2.671, 95%CI:1.160 ～ 6.012） and tumor diameter ≥ 3cm （HR=1.628, 95%CI: 1.017 ～ 2.592）were risk factors for poor survival prognosis in glioma patients. Conclusion YTHDF2 increased and UBXN1 decreased in glioma tissues, both of which are related to WHO grading and tumor diameter, and they are independent factors for evaluating the prognosis of glioma patients.

参考文献/References:

[1] SCHAFF L R, MELLINGHOFF I K. Glioblastoma and other primary brain malignancies in adults: a review[J]. Journal of the American Medical Association , 2023,329(7): 574-587.
[2] CAI Jiayang, HU Yuanyuan, YE Zhang, et al. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma[J]. Frontiers in Immunology, 2022, 13: 1011757.
[3] YU Jie, CHAI Peiwei, XIE Minyue, et al. Histone lactylation drives oncogenesis by facilitating m(6) A reader protein YTHDF2 expression in ocular melanoma[J]. Genome Biology, 2021, 22(1): 85.
[4] LI Jiangfeng, XIE Haiyun, YING Yufan, et al. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer[J]. Molecular Cancer, 2020, 19(1): 152.
[5] MENGUS C, NEUTZNER M, BENTO A C P F, et al. VCP/p97 cofactor UBXN1/SAKS1 regulates mitophagy by modulating MFN2 removal from mitochondria [J]. Autophagy, 2022, 18(1): 171-190.
[6] YIN Xiu, LIU Qingbin, LIU Fen, et al. Emerging roles of non-proteolytic ubiquitination in tumorigenesis [J]. Frontiers in Cell and Developmental Biology, 2022, 10: 944460.
[7] OH J J, HO J N, BYUN S S. ARRDC4 and UBXN1: novel target genes correlated with prostate cancer gleason score[J]. Cancers, 2021, 13(20): 5209.
[8] MO Zongchao, XIN Junyi, CHAI Ruichao, et al. Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations[J]. Cancer biology & Medicine, 2022, 19(10): 1440-1459.
[9] 刁迅, 范绮雨, 耿良栋, 等. 基于生物信息学分析双硫死亡相关基因PDLIM1 mRNA 在多种肿瘤中的表达及临床应用价值[J]. 现代检验医学杂志, 2024,39(1): 36-42, 54. DIAO Xun, FAN Qiyu, GENG Liangdong, et al. Analysis of expression in disulfidptosis-related gene PDLIM1 mRNA in various tumors and its clinical application value based on bioinformatics[J]. Journal of Modern Laboratory Medicine, 2024, 39(1): 36-42, 54.
[10] WANG Liangliang, DOU Xiaoyang, CHEN Shijie, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy [J]. Cancer Cell, 2023, 41(7): 1294-1308, e8.
[11] DIXIT D, PRAGER B C, GIMPLE R C, et al. The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells[J]. Cancer Discovery, 2021, 11(2): 480-499.
[12] FANG Runping, CHEN Xin, ZHANG Sicong, et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma[J]. Nature Communications, 2021, 12(1): 177.
[13] MA Shoubao, SUN Baofa, DUAN Songqi, et al. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells[J]. Nature Immunology, 2023,24(2): 255-266.
[14] LIAO Yuning, LIU Yuan, YU Cuifu, et al. HSP90beta impedes STUB1-induced ubiquitination of YTHDF2 to drive sorafenib resistance in hepatocellular carcinoma[J]. Advanced Science Weinheim Baden Wurttemberg Germany, 2023, 10(27): 2302-23025.
[15] WANG Liangliang, DOU Xiaoyang, CHEN Shijie, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy [J]. Cancer Cell, 2023, 41(7): 1294-1308, e8.
[16] LI Yansheng, LIU Xing, CUI Xiaoteng, et al. LncRNA PRADX-mediated recruitment of PRC2/DDX5 complex suppresses UBXN1 expression and activates NF-κB activity, promoting tumorigenesis[J]. Theranostics, 2021, 11(9): 4516-4530.
[17] LIU Junliang, ZHANG Jinling, ZHANG Guowei, et al. CircMRE11A_013 binds to UBXN1 and integrates ATM activation enhancing lens epithelial cells senescence in age-related cataract[J]. Aging (Albany NY), 2021, 13(4): 5383-5402.
[18] YI Kaikai, CUI Xiaoteng, LIU Xing, et al. PTRF/cavin-1 as a novel RNA-binding protein expedites the NF-κB/PD-L1 axis by stabilizing lncRNA NEAT1 [J]. Frontiers in Immunology, 2021, 12: 802795.
[19] DAN Wenran, ZHONG Liang, ZHANG Zhonghui,et al. RIP1-dependent apoptosis and differentiation regulated by Skp2 and Akt/GSK3β in acute myeloid leukemia[J]. International Journal of Medical Sciences,2022, 19(3): 525-536.
[20] YANG Enyu, FAN Xiaowei, YE Haihan, et al. Exploring the role of ubiquitin regulatory X domain family proteins in cancers: bioinformatics insights,mechanisms, and implications for therapy[J]. Journal of Translational Medicine, 2024, 22(1): 157.
[21] CHAI Ruichao, CHANG Yuzhou, CHANG Xin, et al. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma[J]. Journal of Hematology & Oncology, 2021, 14(1): 109.

备注/Memo

备注/Memo:
基金项目：山东省医药卫生科技发展计划项目（202014050419）。
作者简介：史明旭（1972-），男，本科, 主任医师，研究方向：神经外科，E-mail：simingxu256542@163.com。
通讯作者：宫晶（1973-），女，本科, 副主任医师，研究方向：小儿内科，E-mail：782705168@qq.com。
更新日期/Last Update: 2024-11-15